Educational attainment and response to HAART during initial therapy for HIV-1 infection

Journal of Psychosomatic Research

Volumn 63, Issue 2, 2007, Pages 207-216

  Marc, Linda G ^a,b,c   Testa, Marcia A ^c   Walker, Alexander M ^c   Robbins, Gregroy K ^d   Shafer, Robert W ^e   Anderson, Norman B ^c,f   Berkman, Lisa F ^c  

^a Clinical Trials Unit   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^f AMERICAN PSYCHOLOGICAL ASSOCIATION   (United States)

Author keywords

Adherence self efficacy; Antiretroviral; Educational attainment; HIV AIDS; Regimen failure; Socioeconomic status

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ARTICLE; BEHAVIORAL RESEARCH; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EDUCATIONAL STATUS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SOCIAL STATUS; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS LOAD;

ACHIEVEMENT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PATIENT COMPLIANCE; QUESTIONNAIRES; SELF EFFICACY;

EID: 34447629685     PISSN: 00223999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychores.2007.04.009     Document Type: Article

References (103)

1. + cell depletion and progression to AIDS. Ann Intern Med 118 (1993) 681-688
2. Deeks S. Failure of HIV-1 protease inhibitors to fully suppress viral replication. Implications for salvage therapy. Adv Exp Med Biol 458 (1999) 175-182
3. Deeks S. Determinants of virological response to antiretroviral therapy: implications for long-term strategies. Clin Infect Dis 30 Suppl 2 (2000) S177-S184
4. Deeks S., Hecht F., Swanson M., Elbeik T., Loftus R., Cohen P., et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 13 (1999) F35-F43
5. Deeks S., Hellmann N., Grant R., Parkin N., Petropoulos C., Becker M., et al. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J Infect Dis 179 (1999) 1375-1381
6. Fee E., and Krieger N. Understanding AIDS: historical interpretations and the limits of biomedical individualism. Am J Public Health 83 (1993) 1477-1486
7. Levy J. Pathogenesis of human immunodeficiency virus infection. Microbiol Rev 57 (1993) 183-289
8. Haynes B., Pantaleo G., and Fauci A. Toward an understanding of the correlates of protective immunity to HIV infection. Science 271 (1996) 324-328
9. Kaslow R., Duquesnoy R., VanRaden M., Kingsley L., Marrari M., Friedman H., et al. A1, Cw7, B8, DR3 HLA antigen combination associated with rapid decline of T-helper lymphocytes in HIV-1 infection. A report from the Multicenter AIDS Cohort Study. Lancet 335 (1990) 927-930
10. Soloway B, Friedland G. Antiretroviral failure: a biopsychosocial approach. AIDS Clin Care 2000;12(3):23-255, 30.
11. Doyal L., and Pennell I. The political economy of health (1981), South End Press, Boston
12. Krieger N. Theories for social epidemiology in the 21st century: an ecosocial perspective. Int J Epidemiol 30 (2001) 668-677
13. Krieger N. A glossary for social epidemiology. J Epidemiol Community Health 55 (2001) 693-700
14. Ironson G., O'Cleirigh C., Fletcher M., Laurenceau J., Balbin E., Klimas N., et al. Psychosocial factors predict CD4 and viral load change in men and women with human immunodeficiency virus in the era of highly active antiretroviral treatment. Psychosom Med 67 (2005) 1013-1021
15. del Amo J., del Romero J., Barrasa A., Perez-Hoyos S., Rodriguez C., Diez M., et al. Factors influencing HIV progression in a seroconverter cohort in Madrid from 1985 to 1999. Sex Transm Infect 78 (2002) 255-260
16. Hogg R., Strathdee S., Craib K., O'Shaughnessy M., Montaner J., and Schechter M. Lower socioeconomic status and shorter survival following HIV infection. [comment]. Lancet 344 (1994) 1120-1124
17. Rapiti E., Porta D., Forastiere F., Fusco D., and Perucci C. Socioeconomic status and survival of persons with AIDS before and after the introduction of highly active antiretroviral therapy. Lazio AIDS Surveillance Collaborative Group. Epidemiology 11 (2000) 496-501
18. Schechter M., Hogg R., Aylward B., Craib K., Le T., and Montaner J. Higher socioeconomic status is associated with slower progression of HIV infection independent of access to health care. J Clin Epidemiol 47 (1994) 59-67
19. Wood E., Montaner J., Chan K., Tyndall M., Schechter M., Bangsberg D., et al. Socioeconomic status, access to triple therapy, and survival from HIV-disease since 1996. AIDS 16 (2002) 2065-2072
20. Katz M., Hsu L., Lingo M., Woelffer G., and Schwarcz S. Impact of socioeconomic status on survival with AIDS. Am J Epidemiol 148 (1998) 282-291
21. Junghans C., Low N., Chan P., Witschi A., Vernazza P., and Egger M. Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study. AIDS 13 (1999) 2547-2554
22. Anderson N., and Armstead C. Toward understanding the association of socioeconomic status and health: a new challenge for the biopsychosocial approach. Psychosom Med 57 (1995) 213-225
23. Johnson M., Chesney M., Goldstein R., Remien R., Catz S., Gore-Felton C., et al. Positive provider interactions, adherence self-efficacy, and adherence to antiretroviral medications among HIV-infected adults: a mediation model. AIDS Patient Care STDs 20 (2006) 258-268
24. Dohrenwend B. Social status and stressful life events. J Pers Soc Psychol 28 (1973) 225-235
25. Dohrenwend B., and Dohrenwend B. Social status and psychological disorder; a causal inquiry (1969), Wiley-Interscience, New York
26. Solomon G., Ironson G., and Balbin E. Psychoneuroimmunology and HIV/AIDS. Ann N Y Acad Sci 917 (2000) 500-504
27. Liem R., and Liem J. Social class and mental illness reconsidered: the role of economic stress and social support. J Health Soc Behav 19 (1978) 139-156
28. McLeod J., and Kessler R. Socioeconomic status differences in vulnerability to undesirable life events. J Health Soc Behav 31 (1990) 162-172
29. Kessler R., and Cleary P. Social class and psychological distress. Am Sociol Rev 45 (1980) 463-478
30. Marmot M., Ryff C., Bumpass L., Shipley M., and Marks N. Social inequalities in health: next questions and converging evidence. Soc Sci Med 44 (1997) 901-910
31. Marmot M., and Wilkinson R. Social determinants of health (1999), Oxford University Press, Oxford
32. Lynch J., Kaplan G., and Salonen J. Why do poor people behave poorly? Variation in adult health behaviours and psychosocial characteristics by stages of the socioeconomic lifecourse. Soc Sci Med 44 (1997) 809-819
33. Brunner E. Commentary: education, education, education. [comment]. Int J Epidemiol 30 (2001) 1126-1128
34. Pincus T., Callahan L., and Burkhauser R. Most chronic diseases are reported more frequently by individuals with fewer than 12 years of formal education in the age 18-64 United States population. J Chronic Dis 40 (1987) 865-874
35. Wilkinson R. Unhealthy societies: the afflictions of inequality (1996), Routledge, London
36. Yen I., and Kaplan G. Poverty area residence and changes in depression and perceived health status: evidence from the Alameda County Study. Int J Epidemiol 28 (1999) 90-94
37. Aneshensel C. Social stress: theory and research. Annu Rev Sociology (1992) 15-38
38. Aneshensel C., Rutter C., and Lachenbruch P. Social structure, stress, and mental health: competing conceptual and analytic models. Am Sociol Rev 56 (1991) 166-178
39. Turner R., Wheaton B., and Lloyd D. The epidemiology of social stress. Am Sociol Rev 60 (1995) 104-125
40. Brunner E. Stress and the biology of inequality. BMJ 314 (1997) 1472-1476
41. Cohen S., Frank E., Doyle W., Skoner D., Rabin B., and Gwaltney J. Types of stressors that increase susceptibility to the common cold in healthy adults. [comment]. Health Psychol 17 (1998) 214-223
42. Cohen S., Line S., Manuck S., Rabin B., Heise E., and Kaplan J. Chronic social stress, social status, and susceptibility to upper respiratory infections in nonhuman primates. [comment]. Psychosom Med 59 (1997) 213-221
43. Kiecolt-Glaser J., and Glaser R. Psychoneuroimmunology and health consequences: data and shared mechanisms. Psychosom Med 57 (1995) 269-274
44. Chen E., Fisher E., Bacharier L., and Strunk R. Socioeconomic status, stress, and immune markers in adolescents with asthma. Psychosom Med 65 (2003) 984-992
45. Jemmott J., and McClelland D. Secretory IgA as a measure of resistance to infectious disease: comments on Stone, Cox, Valdimarsdottir, and Neale. Behav Med 15 (1989) 63-71
46. Evans P., Der G., Ford G., Hucklebridge F., Hunt K., and Lambert S. Social class, sex, and age differences in mucosal immunity in a large community sample. Brain Behav Immun 14 (2000) 41-48
47. Cohen S. Social status and susceptibility to respiratory infections. Ann N Y Acad Sci 896 (1999) 246-253
48. Cohen S., Miller G., and Rabin B. Psychological stress and antibody response to immunization: a critical review of the human literature. Psychosom Med 63 (2001) 7-18
49. + cell decline in HIV infection. J Psychosom Res 42 (1997) 379-390
50. Evans D., Leserman J., Perkins D., Stern R., Murphy C., Tamul K., et al. Stress-associated reductions of cytotoxic T lymphocytes and natural killer cells in asymptomatic HIV infection. Am J Psychiatry 152 (1995) 543-550
51. Evans D., Leserman J., Perkins D., Stern R., Murphy C., Zheng B., et al. Severe life stress as a predictor of early disease progression in HIV infection. Am J Psychiatry 154 (1997) 630-634
52. Leserman J. The effects of depression, stressful life events, social support, and coping on the progression of HIV infection. Curr Psychiatry Rep 2 (2000) 495-502
53. Leserman J. The effects of stressful life events, coping, and cortisol on HIV infection. CNS Spectr 8 (2003) 25-30
54. Leserman J., Jackson E., Petitto J., Golden R., Silva S., Perkins D., et al. Progression to AIDS: the effects of stress, depressive symptoms, and social support. Psychosom Med 61 (1999) 397-406
55. Leserman J., Petitto J., Golden R., Gaynes B., Gu H., Perkins D., et al. Impact of stressful life events, depression, social support, coping, and cortisol on progression to AIDS. Am J Psychiatry 157 (2000) 1221-1228
56. Leserman J., Petitto J., Gu H., Gaynes B., Barroso J., Golden R., et al. Progression to AIDS, a clinical AIDS condition and mortality: psychosocial and physiological predictors. Psychol Med 32 (2002) 1059-1073
57. Leserman J., Petitto J., Perkins D., Folds J., Golden R., and Evans D. Severe stress, depressive symptoms, and changes in lymphocyte subsets in human immunodeficiency virus-infected men. A 2-year follow-up study. Arch Gen Psychiatry 54 (1997) 279-285
58. Patterson T., Semple S., Temoshok L., Atkinson J., McCutchan J., Straits-Troster K., et al. Stress and depressive symptoms prospectively predict immune change among HIV-seropositive men. HIV Neurobehavioral Research Center Group. Psychiatry 58 (1995) 299-312
59. Kemeny M., and Dean L. Effects of AIDS-related bereavement on HIV progression among New York City gay men. AIDS Educ Prev 7 Suppl 5 (1995) 36-47
60. Antoni M., Cruess D., Klimas N., Maher K., Cruess S., Kumar M., et al. Stress management and immune system reconstitution in symptomatic HIV-infected gay men over time: effects on transitional naive T cells (CD4(+)CD45RA(+)CD29(+)). Am J Psychiatry 159 (2002) 143-145
61. Herek G., Capitanio J., and Widaman K. HIV-related stigma and knowledge in the United States: prevalence and trends, 1991-1999. Am J Public Health 92 (2002) 371-377
62. Chesney M., and Antoni M. Innovative approaches to health psychology: prevention and treatment lessons from AIDS (2002), American Psychological Association, Washington, DC
63. Endler N., and Parker J. Multidimensional assessment of coping: a critical evaluation. J Pers Soc Psychol 58 (1990) 844-854
64. Lazarus R., and Folkman S. Stress, appraisal, and coping (1984), Springer Pub. Co., New York
65. Chesney M., Chambers D., Taylor J., Johnson L., and Folkman S. Coping effectiveness training for men living with HIV: results from a randomized clinical trial testing a group-based intervention. Psychosom Med 65 (2003) 1038-1046
66. Lutgendorf S., Antoni M., Ironson G., Klimas N., Kumar M., Starr K., et al. Cognitive-behavioral stress management decreases dysphoric mood and herpes simplex virus-type 2 antibody titers in symptomatic HIV-seropositive gay men. J Consult Clin Psychol 65 (1997) 31-43
67. MAChesney, personal communication, May 2006.
68. + persons naïve to antiretroviral therapy: a cross-sectional survey. J AIDS Behav 8 (2004) 141-150
69. Robbins G., De Gruttola V., Shafer R., Smeaton L., Snyder S., Pettinelli C., et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. [see comment]. N Engl J Med 349 (2003) 2293-2303
70. Shafer R., Smeaton L., Robbins G., De Gruttola V., Snyder S., and D'Aquila R. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. [see comment]. N Engl J Med 349 (2003) 2304-2315
71. Smeaton L., DeGruttola V., Robbins G., and Shafer R. ACTG (AIDS Clinical Trials Group) 384: a strategy trial comparing consecutive treatments for HIV-1. [comment]. Controlled Clin Trials 22 (2001) 142-159
72. Chesney M., Ickovics J., Chambers D., Gifford A., Neidig J., Zwickl B., et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee and Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 12 (2000) 255-266
73. Bandura A. Social foundations of thought and action: a social cognitive theory (1986), Prentice-Hall, Englewood Cliffs (NJ)
74. Stata Corporation. Stata user's guide: release 9. Release 9 ed (2005), Stata Corp., College Station, TX
75. SPSS, Inc. SPSS for Windows 10.0 (2001), SPSS, Inc, Chicago (IL)
76. CDC. Centers for Disease Control and Prevention: guidelines for using antiretroviral agents among HIV-infected adults and adolescents, 2002.
77. Weinstock H., Zaidi I., Heneine W., Bennett D., Garcia-Lerma J., Douglas J., et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 189 (2004) 2174-2180
78. Havlir D., Marschner I., Hirsch M., Collier A., Tebas P., Bassett R., et al. Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N Engl J Med 339 (1998) 1261-1268
79. Miller V., Phillips A., Rottmann C., Staszewski S., Pauwels R., Hertogs K., et al. Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure. J Infect Dis 177 (1998) 1521-1532
80. Rey D., Hughes M., Pi J., Winters M., Merigan T., and Katzenstein D. HIV-1 reverse transcriptase codon 215 mutation in plasma RNA: immunologic and virologic responses to zidovudine. AIDS Clin Trials Group Study 17 (1998) 203-208
81. D'Aquila R., Johnson V., Welles S., Japour A., Kuritzkes D., DeGruttola V., et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. Ann Intern Med 122 (1995) 401-408
82. Farmer P., Leandre F., Mukherjee J., Claude M., Nevil P., Smith-Fawzi M., et al. Community-based approaches to HIV treatment in resource-poor settings. Lancet 358 (2001) 404-409
83. Coetzee D., Boulle A., Hildebrand K., Asselman V., Van G., and Cutsem E. Promoting adherence to antiretroviral therapy: the experience from a primary care setting in Khayelitsha, South Africa. AIDS 18 Suppl 3 (2004) S27-S31
84. Orrell C., Bekker L., and Wood R. Adherence to antiretroviral therapy-achievable in the South African context?. S Afr Med J 91 (2001) 483-484
85. Lee S., and Kavanaugh A. A need for greater reporting of socioeconomic status and race in clinical trials. Ann Rheum Dis 63 (2004) 1700-1701
86. Cole S., and Kemeny M. Psychobiology of HIV infection. Crit Rev Neurobiol 11 (1997) 289-321
87. Robinson F., Mathews H., and Witek-Janusek L. Stress and HIV disease progression: psychoneuroimmunological framework. J Assoc Nurses AIDS Care 10 (1999) 21-31
88. Kiecolt-Glaser J., and Glaser R. Psychological influences on immunity. Implications for AIDS. Am Psychol 43 (1988) 892-898
89. Kumar M., Kumar A., Waldrop D., Antoni M., and Eisdorfer C. HIV-1 infection and its impact on the HPA axis, cytokines, and cognition. Stress 6 (2003) 167-172
90. Kumar M., Kumar A., Waldrop D., Antoni M., Schneiderman N., and Eisdorfer C. The HPA axis in HIV-1 infection. J Acquir Immune Defic Syndr 31 Suppl 2 (2002) S89-S93
91. McEwen B. Protective and damaging effects of stress mediators. N Engl J Med 338 (1998) 171-179
92. McEwen B. Stress, adaptation, and disease. Allostasis and allostatic load. Ann N Y Acad Sci 840 (1998) 33-44
93. Sapolsky R., Alberts S., and Altmann J. Hypercortisolism associated with social subordinance or social isolation among wild baboons. Arch Gen Psychiatry 54 (1997) 1137-1143
94. Abbott D., Keverne E., Bercovitch F., Shively C., Mendoza S., Saltzman W., et al. Are subordinates always stressed? A comparative analysis of rank differences in cortisol levels among primates. Horm Behav 43 (2003) 67-82
95. Nehete P., Schapiro S., Perlman J., and Sastry K. Influence of psychosocial factors on immune status in rhesus monkeys: implications for HIV research in non-human primates: Proceedings and Abstracts of the 17th Annual Symposium on Nonhuman Primate Models for AIDS, New Orleans, LA, USA, October 6-9, 1999. J Med Primatol 29 (August 2002) 3-4
96. Schapiro S., Nehete P., Perlman J., Bloomsmith M., and Sastry K. Effects of dominance status and environmental enrichment on cell-mediated immunity in rhesus macaques. Appl Anim Behav Sci 56 (1998) 319-332
97. Cole S., Naliboff B., Kemeny M., Griswold M., Fahey J., and Zack J. Impaired response to HAART in HIV-infected individuals with high autonomic nervous system activity. Proc Natl Acad Sci U S A 98 (2001) 12695-12700
98. Markham P., Salahuddin S., Veren K., Orndorff S., and Gallo R. Hydrocortisone and some other hormones enhance the expression of HTLV-III. Int J Cancer 37 (1986) 67-72
99. Krieger N., Williams D., and Moss N. Measuring social class in us public health research-concepts, methodologies, and guidelines. Ann Rev Public Health 18 (1997) 341-378
100. Shibata M., Flather M., de Arenaza D., Wang D., and O'Shea J. Potential impact of socioeconomic differences on clinical outcomes in international clinical trials. Am Heart J 141 (2001) 1019-1024
101. Anderson N. Solving the puzzle of SES and health. Ann N Y Acad Sci 896 (1999) 302-312
102. Anderson N., and Scott P. Making the case for psychophysiology during the era of molecular biology. Psychophysiology 36 (1999) 1-13
103. Marc LG. Social determinants of therapeutic effectiveness in initial therapy for HIV-1 infection. Doctor of science thesis. Boston: Harvard School of Public Health, 2005.